<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: highlights", fill: "#8601af"},
{source: "2: highlights", target: "2: possible impact", fill: "#8601af"},
{source: "2: possible impact", target: "2: factors on future", fill: "#8601af"},
{source: "2: factors on future", target: "2: operations", fill: "#8601af"},
{source: "2: highlights", target: "12: currently market", fill: "#ec5800"},
{source: "12: currently market", target: "12: Core Companion Animal Health ", fill: "#ec5800"},
{source: "12: Core Companion Animal Health ", target: "12: veterinarians", fill: "#ec5800"},
{source: "12: veterinarians", target: "12: approximately", fill: "#ec5800"},
{source: "12: approximately", target: "12: independent", fill: "#ec5800"},
{source: "12: independent", target: "12: thirdparty", fill: "#ec5800"},
{source: "12: thirdparty", target: "12: distributors", fill: "#ec5800"},
{source: "12: distributors", target: "12: product line", fill: "#ec5800"},
{source: "12: product line", target: "12: direct sales force", fill: "#ec5800"},
{source: "12: currently market", target: "13: effectively market", fill: "#b38b6d"},
{source: "13: effectively market", target: "13: direct sales force as well as sales personnel", fill: "#b38b6d"},
{source: "13: direct sales force as well as sales personnel", target: "13: distributors", fill: "#b38b6d"},
{source: "13: distributors", target: "13: arrangements with third parties", fill: "#b38b6d"},
{source: "13: arrangements with third parties", target: "13: market distribute", fill: "#b38b6d"},
{source: "13: effectively market", target: "14: addition most", fill: "#b7410e"},
{source: "14: addition most", target: "14: distributor agreements", fill: "#b7410e"},
{source: "14: distributor agreements", target: "14: competitors effectively prohibits", fill: "#b7410e"},
{source: "14: competitors effectively prohibits", target: "14: distributors from selling competitive", fill: "#b7410e"},
{source: "14: distributors from selling competitive", target: "14: diagnostic instruments", fill: "#b7410e"},
{source: "14: diagnostic instruments", target: "14: heartworm diagnostic", fill: "#b7410e"},
{source: "14: addition most", target: "21: must contract", fill: "#afeeee"},
{source: "21: must contract", target: "21: manufacture", fill: "#afeeee"},
{source: "21: manufacture", target: "21: ourselves current", fill: "#afeeee"},
{source: "21: ourselves current", target: "21: future products", fill: "#afeeee"},
{source: "21: future products", target: "21: appropriate quantity quality", fill: "#afeeee"},
{source: "21: must contract", target: "22: products must", fill: "#fad6a5"},
{source: "22: products must", target: "22: available on", fill: "#fad6a5"},
{source: "22: available on", target: "22: timely basis", fill: "#fad6a5"},
{source: "22: timely basis", target: "22: regulatory requirements", fill: "#fad6a5"},
{source: "22: products must", target: "29: agreements", fill: "#de5d83"},
{source: "29: agreements", target: "29: ensure supply", fill: "#de5d83"},
{source: "29: ensure supply", target: "29: major product offerings through at least", fill: "#de5d83"},
{source: "29: major product offerings through at least", target: "29: compliance with such agreements there", fill: "#de5d83"},
{source: "29: compliance with such agreements there", target: "29: suppliers will", fill: "#de5d83"},
{source: "29: suppliers will", target: "29: obligations under", fill: "#de5d83"},
{source: "29: obligations under", target: "29: compel them", fill: "#de5d83"},
{source: "29: agreements", target: "30: product rights upon expiration", fill: "#8878c3"},
{source: "30: product rights upon expiration", target: "30: termination", fill: "#8878c3"},
{source: "30: termination", target: "30: existing agreement", fill: "#8878c3"},
{source: "30: product rights upon expiration", target: "46: agreements may", fill: "#5a4fcf"},
{source: "46: agreements may", target: "46: minimum purchases andor sales", fill: "#5a4fcf"},
{source: "46: minimum purchases andor sales", target: "46: significantly harmed", fill: "#5a4fcf"},
{source: "46: significantly harmed", target: "46: requirements", fill: "#5a4fcf"},
{source: "46: requirements", target: "46: lose product rights", fill: "#5a4fcf"},
{source: "46: agreements may", target: "62: product development", fill: "#96c"},
{source: "62: product development", target: "62: development", fill: "#96c"},
{source: "62: development", target: "62: could delay", fill: "#96c"},
{source: "62: could delay", target: "62: regulatory submissions", fill: "#96c"},
{source: "62: regulatory submissions", target: "62: commercialization", fill: "#96c"},
{source: "62: commercialization", target: "62: miss key opportunities", fill: "#96c"},
{source: "62: product development", target: "63: intellectual property rights", fill: "#b76e79"},
{source: "63: intellectual property rights", target: "68: agreement", fill: "#bd33a4"},
{source: "68: agreement", target: "68: which grants distribution", fill: "#bd33a4"},
{source: "68: which grants distribution", target: "68: marketing rights", fill: "#bd33a4"},
{source: "68: marketing rights", target: "68: heartworm", fill: "#bd33a4"},
{source: "68: agreement", target: "START_HERE", fill: "#bd33a4"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Met_Operations">Met Operations</a></td>
      <td>Met Operations, also known as Met Ops, is one of the four business groups which forms the Metropolitan Police Service. It was created during the 2018-19 restructuring of the service, amalgamating many of its functions from the Operations side of the Specialist Crime &amp; Operations Directorate formed in 2012, with the Specialist Crime side of that Directorate placed under the new Frontline Policing Directorate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Foodservice_distributor">Foodservice distributor</a></td>
      <td>A food service distributor is a company that provides food and non-food products to restaurants, cafeterias, industrial caterers, hospitals, schools/colleges/universities, nursing homes, and anywhere food is served away from the home.\n\n\n== Description ==\nA food service distributor functions as an intermediary between food manufacturers and the food service operator (usually a chef, food service director, food and beverage manager, and independent food preparation businesses operator owners.)  The distributor purchases, stores, sells, and delivers those products, providing food service operators with access to items from a wide variety of manufacturers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Good_Friday_Agreement">Good Friday Agreement</a></td>
      <td>The Good Friday Agreement (GFA), or Belfast Agreement (Irish: Comhaontú Aoine an Chéasta or Comhaontú Bhéal Feirste; Ulster-Scots: Guid Friday Greeance or Bilfawst Greeance), is a pair of agreements signed on 10 April 1998 that ended most of the violence of the Troubles, a political conflict in Northern Ireland that had ensued since the late 1960s. It was a major development in the Northern Ireland peace process of the 1990s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenuptial_agreement">Prenuptial agreement</a></td>
      <td>A prenuptial agreement, antenuptial agreement, or premarital agreement (commonly referred to as a prenup), is a written contract entered into by a couple prior to marriage or a civil union that enables them to select and control many of the legal rights they acquire upon marrying, and what happens when their marriage eventually ends by death or divorce. Couples enter into a written prenuptial agreement to supersede many of the default marital laws that would otherwise apply in the event of divorce, such as the laws that govern the division of property, retirement benefits, savings, and the right to seek alimony (spousal support) with agreed-upon terms that provide certainty and clarify their marital rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Paris_Agreement">Paris Agreement</a></td>
      <td>The Paris Agreement (French: Accord de Paris), often referred to as the Paris Accords or the Paris Climate Accords, is an international treaty on climate change, adopted in 2015. It covers climate change mitigation, adaptation, and finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_requirements_document">Market requirements document</a></td>
      <td>A market requirements document (MRD) in project management and systems engineering, is a document that expresses the customer's wants and needs for the product or service.\nIt is typically written as a part of product marketing or product management.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Functional_requirement">Functional requirement</a></td>
      <td>In software engineering and systems engineering, a functional requirement defines a function of a system or its component, where a function is described as a specification of behavior between inputs and outputs.Functional requirements may involve calculations, technical details, data manipulation and processing, and other specific functionality that define what a system is supposed to accomplish. Behavioral requirements describe all the cases where the system uses the functional requirements, these are captured in use cases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Haavara_Agreement">Haavara Agreement</a></td>
      <td>The Haavara Agreement (Hebrew: הֶסְכֵּם הַעֲבָרָה‎  Translit.: heskem haavara   Translated: "transfer agreement") was an agreement between Nazi Germany and Zionist German Jews signed on 25 August 1933. The agreement was finalized after three months of talks by the Zionist Federation of Germany, the Anglo-Palestine Bank (under the directive of the Jewish Agency) and the economic authorities of Nazi Germany.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Simla_Agreement">Simla Agreement</a></td>
      <td>The Simla Agreement, also spelled Shimla Agreement, was a peace treaty signed between India and Pakistan on 2 July 1972 in Shimla, the capital city of the Indian state of Himachal Pradesh. It followed the Indo-Pakistani War of 1971, which began after India intervened in East Pakistan as an ally of Bengali rebels who were fighting against Pakistani state forces in the Bangladesh Liberation War.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/UKUSA_Agreement">UKUSA Agreement</a></td>
      <td>The United Kingdom – United States of America Agreement (UKUSA,  yoo-koo-SAH) is a multilateral agreement for cooperation in signals intelligence between Australia, Canada, New Zealand, the United Kingdom, and the United States. The alliance of intelligence operations is also known as the Five Eyes.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>HESKA CORP      Item 1A Risk Factors               Our future operating results <font color="blue">may vary <font color="blue">substantially</font> from period</font> to period     due  to a number of factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>The     following discussion <font color="blue">highlights</font> these factors and the <font color="blue">possible impact</font> of     these <font color="blue">factors on future</font> results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the following     <font color="blue">factors actually</font> occur, our business, <font color="blue">financial condition</font> or results of     <font color="blue">operations</font> could be harmed</td>
    </tr>
    <tr>
      <td>In that case, the price of our <font color="blue">common stock</font>     could decline and you could experience losses on your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">successfully</font> market, sell and distribute our products</td>
    </tr>
    <tr>
      <td>We may not <font color="blue">successfully</font> develop and maintain marketing, <font color="blue">distribution</font> or     <font color="blue">sales <font color="blue">capabilities</font></font>, and we may not be able to make <font color="blue">arrangements with third</font>     parties to perform these <font color="blue"><font color="blue">activities</font> on</font> satisfactory terms</td>
    </tr>
    <tr>
      <td>If our marketing,     sales and <font color="blue"><font color="blue">distribution</font> strategy</font> is <font color="blue">unsuccessful</font>, our ability to sell our     <font color="blue">products will</font> be <font color="blue">negatively impacted</font> and our <font color="blue">revenues <font color="blue">will decrease</font></font></td>
    </tr>
    <tr>
      <td>The market for <font color="blue">companion animal healthcare products</font> is <font color="blue">highly fragmented</font></td>
    </tr>
    <tr>
      <td>Because our <font color="blue">Core Companion Animal Health </font><font color="blue"><font color="blue">proprietary</font> products</font> are <font color="blue">generally</font>     available  only  to  <font color="blue">veterinarians</font>  or <font color="blue">by prescription</font> and our medical     <font color="blue">instruments</font> require <font color="blue">technical training</font> to operate, we <font color="blue">ultimately sell</font> our     <font color="blue">Core Companion Animal Health </font><font color="blue">products only</font> to or through <font color="blue">veterinarians</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">acceptance</font> of our products by <font color="blue">veterinarians</font> is critical to our success</td>
    </tr>
    <tr>
      <td>Changes in our ability to obtain or maintain such <font color="blue">acceptance</font> or changes in     <font color="blue">veterinary</font> medical practice could <font color="blue"><font color="blue">significant</font>ly</font> decrease our anticipated     sales</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently market</font> our <font color="blue">Core Companion Animal Health </font>products in the United     States to <font color="blue">veterinarians</font> through <font color="blue">approximately</font> 10 <font color="blue">independent</font> third-party     <font color="blue"><font color="blue">distributor</font>s</font>  who  carry our full line of <font color="blue">Core Companion Animal Health </font>    products, <font color="blue">approximately</font> 14 <font color="blue">independent</font> third-party <font color="blue"><font color="blue">distributor</font>s</font> who carry                                           12     ______________________________________________________________________         portions of our <font color="blue">Core Companion Animal Health </font><font color="blue">product line</font> and through a     <font color="blue">direct sales force</font> of <font color="blue">approximately</font> 28 <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td>To be successful, we     will have to <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> market</font> our products and continue to develop and     train our <font color="blue">direct sales force</font> as well as sales personnel of our <font color="blue"><font color="blue">distributor</font>s</font>     and rely on other <font color="blue">arrangements with third</font> parties to market, distribute and     sell our products</td>
    </tr>
    <tr>
      <td>In addition, most of our <font color="blue"><font color="blue">distributor</font> <font color="blue"><font color="blue">agreement</font>s</font></font> can be     <font color="blue">terminated on</font> 60 days notice and we believe that IDEXX, one of our largest     <font color="blue">competitors</font>, <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> prohibits</font> its <font color="blue"><font color="blue">distributor</font>s</font> from selling <font color="blue">competitive</font>     products, including our <font color="blue">diagnostic</font> <font color="blue">instruments</font> and <font color="blue"><font color="blue">heartworm</font> <font color="blue">diagnostic</font></font>     tests</td>
    </tr>
    <tr>
      <td>We believe this restriction <font color="blue"><font color="blue">significant</font>ly</font> limits our ability to     engage  national  <font color="blue"><font color="blue">distributor</font>s</font>  to  sell our full line of products and     <font color="blue"><font color="blue">significant</font>ly</font> restricts our ability to market our products to <font color="blue">veterinarians</font></td>
    </tr>
    <tr>
      <td>In 2002, one of our largest <font color="blue"><font color="blue">distributor</font>s</font> informed us that they were going to     carry IDEXX products and that they <font color="blue">no longer would</font> carry our <font color="blue">diagnostic</font>     <font color="blue">instruments</font> and <font color="blue"><font color="blue">heartworm</font> <font color="blue">diagnostic</font></font> tests</td>
    </tr>
    <tr>
      <td>In late 2004, this <font color="blue">distributor</font>     acquired another of our <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>We believe IDEXX <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> prohibits</font>     this <font color="blue">distributor</font> from carrying our <font color="blue">diagnostic</font> <font color="blue">instruments</font> and <font color="blue">heartworm</font>     <font color="blue">diagnostic</font> tests as a condition for having access to buy the IDEXX product     line</td>
    </tr>
    <tr>
      <td>The loss of products or     delays in <font color="blue">product <font color="blue">availability</font> from one</font> or more third-party supplier could     <font color="blue"><font color="blue">substantially</font> harm</font> our business</td>
    </tr>
    <tr>
      <td>To  be  successful, we <font color="blue">must contract</font> for the supply of, or <font color="blue">manufacture</font>     ourselves, current and <font color="blue">future products</font> of <font color="blue">appropriate</font> quantity, quality and     cost</td>
    </tr>
    <tr>
      <td>Such <font color="blue">products must</font> be <font color="blue">available on</font> a <font color="blue">timely basis</font> and be in compliance     with any <font color="blue"><font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></font></td>
    </tr>
    <tr>
      <td>Failure to do so could <font color="blue"><font color="blue">substantially</font> harm</font>     our business</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">currently rely on</font> <font color="blue">third party</font> suppliers</font> to <font color="blue">manufacture</font> those products we     do not <font color="blue">manufacture</font> ourselves</td>
    </tr>
    <tr>
      <td>Products <font color="blue">provided by</font> these <font color="blue">suppliers represent</font>     a majority of our revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently rely on</font> these suppliers for our     <font color="blue">veterinary</font> <font color="blue">diagnostic</font> and patient monitoring <font color="blue">instruments</font> and consumable     supplies for these <font color="blue">instruments</font>, for certain of our point-of-care <font color="blue">diagnostic</font>     and other tests, for the <font color="blue">manufacture</font> of our <font color="blue">allergy immunotherapy treatment</font>     products as well as for the <font color="blue">manufacture</font> of other products</td>
    </tr>
    <tr>
      <td>Major suppliers     who <font color="blue">sell us products</font> they <font color="blue">manufacture</font> which are responsible for more than 5prca     or  more  of  our  revenue  are  i-STAT  <font color="blue">Corporation </font>(a unit of Abbott     Laboratories), Arkray Global Business, Inc, Boule Medical AB and Quidel</td>
    </tr>
    <tr>
      <td>We     often purchase products from our <font color="blue">suppliers under <font color="blue"><font color="blue">agreement</font>s</font></font> that are of     limited  duration or <font color="blue">potentially</font> can be <font color="blue">terminated on</font> an <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>Although we believe we have <font color="blue"><font color="blue">agreement</font>s</font> in place to <font color="blue">ensure supply</font> of our     <font color="blue">major product offerings through at least</font> the end of 2006 and we believe we     are in <font color="blue">compliance with</font> such <font color="blue"><font color="blue">agreement</font>s</font>, there can be no assurance that our     <font color="blue">suppliers will</font> be able to meet their <font color="blue"><font color="blue">obligations</font> under</font> these <font color="blue"><font color="blue">agreement</font>s</font> or     that we will be able to <font color="blue">compel them</font> to do so</td>
    </tr>
    <tr>
      <td>Risks of relying on suppliers     include:         •                  The loss of <font color="blue">product rights upon expiration</font> or <font color="blue">termination</font>     of an <font color="blue">existing <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>Unless we are able to find an <font color="blue">alternate supply</font> of     a similar product, we would not be able to continue to offer our customers     the <font color="blue">same breadth</font> of products and our sales and operating results would     likely  suffer</td>
    </tr>
    <tr>
      <td>In  the case of an instrument supplier, we <font color="blue">could also</font>     <font color="blue">potentially</font> suffer the loss of sales of consumable supplies, <font color="blue">which would</font> be     <font color="blue">significant</font> in cases where we have built a <font color="blue">significant</font> <font color="blue">installed base</font>,     <font color="blue">further harming</font> our <font color="blue">sales prospects</font> and <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>Even if we were able     to find an <font color="blue">alternate supply</font>, we <font color="blue"><font color="blue">would likely</font> face increased <font color="blue">competition</font> from</font>     the <font color="blue">product whose rights</font> we lost being <font color="blue">marketed by</font> a <font color="blue">third party</font> or the     <font color="blue">former supplier</font> and it may take us <font color="blue">additional</font> time and expense to gain the     <font color="blue"><font color="blue">necessary</font> approvals</font> and launch an <font color="blue">alternative product</font></td>
    </tr>
    <tr>
      <td>•                  High <font color="blue">switching costs</font></td>
    </tr>
    <tr>
      <td>In certain of our <font color="blue">medical products</font>     we would lose the <font color="blue">consumable revenues from</font> the <font color="blue">installed base</font> of those     <font color="blue">instruments</font> if we were to switch to a <font color="blue">competitive</font> instrument</td>
    </tr>
    <tr>
      <td>If we need to     change to other <font color="blue">commercial <font color="blue">manufacturing</font> contractors</font> for certain of our     regulated products, <font color="blue">additional</font> <font color="blue">regulatory</font> licenses or <font color="blue">approvals must</font> be     obtained for these <font color="blue">contractors prior</font> to our use</td>
    </tr>
    <tr>
      <td>This would require new     testing and <font color="blue">compliance <font color="blue">inspections</font> prior</font> to sale thus resulting in potential     delays</td>
    </tr>
    <tr>
      <td>Any new <font color="blue">manufacture</font>r would have to be educated in, or develop     <font color="blue">substantially</font> equivalent processes <font color="blue">necessary</font> for the production of our     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">likely would</font>                                           13     ______________________________________________________________________         have to train our salesforce, <font color="blue">distribution</font> network employees and customer     support  <font color="blue">organization</font>  on  the new product and spend <font color="blue">significant</font> funds     marketing the new product to our <font color="blue">customer base</font></td>
    </tr>
    <tr>
      <td>•                  The <font color="blue">involuntary</font> or <font color="blue">voluntary discontinuation</font> of a product     line</td>
    </tr>
    <tr>
      <td>Unless we are able to find an <font color="blue">alternate supply</font> of a similar product in     this or similar <font color="blue">circumstances with</font> any product, we would not be able to     continue to offer our customers the <font color="blue">same breadth</font> of products and our sales     <font color="blue"><font color="blue">would likely</font> suffer</font></td>
    </tr>
    <tr>
      <td>Even if we are able to identify an <font color="blue">alternate supply</font>, it     may take us <font color="blue">additional</font> time and expense to gain the <font color="blue"><font color="blue">necessary</font> approvals</font> and     launch an <font color="blue">alternative product</font>, especially if the product is <font color="blue">discontinued</font>     <font color="blue">unexpectedly</font></td>
    </tr>
    <tr>
      <td>•                   <font color="blue">Inability  </font>to  meet  minimum  <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Current     </font><font color="blue"><font color="blue">agreement</font>s</font>, or <font color="blue"><font color="blue">agreement</font>s</font> we <font color="blue">may negotiate</font> in the future, may commit us to     <font color="blue">certain minimum purchase</font> or other spending <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>It is possible we     will not be able to create the <font color="blue">market demand</font> to meet such <font color="blue">obligations</font>, which     could create a drain on our <font color="blue">financial resources</font> and liquidity</td>
    </tr>
    <tr>
      <td>Some such     <font color="blue"><font color="blue">agreement</font>s</font> may require minimum purchases and/or sales to maintain product     rights and we may be <font color="blue"><font color="blue">significant</font>ly</font> harmed if we are unable to meet such     <font color="blue"><font color="blue">requirement</font>s</font> and <font color="blue">lose product rights</font></td>
    </tr>
    <tr>
      <td>•                  Loss of <font color="blue">exclusivity</font></td>
    </tr>
    <tr>
      <td>Current <font color="blue"><font color="blue">agreement</font>s</font>, or <font color="blue"><font color="blue">agreement</font>s</font> we     <font color="blue">may negotiate</font> in the future, with suppliers may require us to <font color="blue">meet minimum</font>     <font color="blue">annual sales levels</font> to maintain our <font color="blue">position as</font> the exclusive <font color="blue">distributor</font> of     these products</td>
    </tr>
    <tr>
      <td>We may not meet these <font color="blue">minimum sales levels</font> in the future and     maintain <font color="blue">exclusivity</font> over the <font color="blue">distribution</font> and sale of these products</td>
    </tr>
    <tr>
      <td>If we     are  not  the exclusive <font color="blue">distributor</font> of these products, <font color="blue">competition</font> may     increase</td>
    </tr>
    <tr>
      <td>•                  Limited <font color="blue">capacity</font> or ability to scale <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>If market     demand for our <font color="blue">products increases suddenly</font>, our <font color="blue">current suppliers might</font> not     be able to fulfill our commercial needs, <font color="blue">which would</font> require us to seek new     <font color="blue"><font color="blue">manufacturing</font> arrangements</font> and may result in substantial delays in meeting     <font color="blue">market demand</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">consistently</font> generate</font> more demand for a <font color="blue">product than</font> a     <font color="blue">given supplier</font> is capable of handling, it could lead to large <font color="blue">backorders</font> and     <font color="blue">potentially</font> lost sales to <font color="blue">competitive</font> products that are <font color="blue">readily available</font></td>
    </tr>
    <tr>
      <td>This could require us to seek or <font color="blue">fund new sources</font> of supply, which may be     <font color="blue">difficult</font> to <font color="blue">find unless</font> it is <font color="blue">under terms</font> that are <font color="blue">less advantageous</font></td>
    </tr>
    <tr>
      <td>•                  <font color="blue">Inconsistent </font>or inadequate <font color="blue">quality control</font></td>
    </tr>
    <tr>
      <td>We may not be     able to control or <font color="blue">adequately monitor</font> the quality of products we receive     from our suppliers</td>
    </tr>
    <tr>
      <td>Poor <font color="blue">quality items could damage</font> our <font color="blue">reputation with</font> our     customers</td>
    </tr>
    <tr>
      <td>•                  <font color="blue">Regulatory </font>risk</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">manufacturing</font> facility</font> and those of     some  of  our  third  party  suppliers are subject to <font color="blue">ongoing periodic</font>     <font color="blue">unannounced inspection by <font color="blue">regulatory</font> <font color="blue">authorities</font></font>, including the FDA, USDA     and other federal and state agencies for <font color="blue"><font color="blue">compliance with</font> strictly enforced</font>     Good Manufacturing Practices, <font color="blue">regulations</font> and similar <font color="blue">foreign standards</font>, and     we do not have <font color="blue">control over</font> our suppliers’ <font color="blue">compliance with</font> these <font color="blue">regulations</font>     and standards</td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>could <font color="blue">potentially</font> lead to <font color="blue">interruptions</font> in supply     that could cause us to lose sales to <font color="blue">readily available</font> <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>•                  <font color="blue">Developmental </font>delays</td>
    </tr>
    <tr>
      <td>We may experience delays in the     scale-up  quantities  needed  for <font color="blue">product <font color="blue">development</font></font> that <font color="blue">could delay</font>     <font color="blue"><font color="blue">regulatory</font> submissions</font> and <font color="blue">commercialization</font> of our products in <font color="blue">development</font>,     causing us to miss key <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>•                  Limited <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>We may not have     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, or may have to share <font color="blue"><font color="blue">intellectual</font> property</font>     rights, to the products themselves and any <font color="blue">improvements</font> to the <font color="blue">manufacturing</font>     processes or new <font color="blue">manufacturing</font> processes for our products</td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________         <font color="blue"><font color="blue">Potential </font> </font><font color="blue">problems with suppliers such as</font> those discussed above could     <font color="blue">substantially</font> decrease sales, lead to higher costs, damage our reputation     with our <font color="blue">customers due</font> to <font color="blue">factors such as poor quality</font> goods or delays in     order <font color="blue">fulfillment</font>, resulting in our being unable to <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> sell</font> our     products and <font color="blue"><font color="blue">substantially</font> harm</font> our business</td>
    </tr>
    <tr>
      <td>If the <font color="blue">third parties</font> to whom we granted substantial <font color="blue">marketing rights</font> for     certain of our existing products or <font color="blue">future products</font> under <font color="blue">development</font> are     not successful in marketing those products, then our sales and financial     position may suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">agreement</font>s</font> with our corporate marketing partners <font color="blue">generally</font> contain no or     small minimum purchase <font color="blue"><font color="blue">requirement</font>s</font> in order for them to maintain their     exclusive or co-exclusive <font color="blue">marketing rights</font></td>
    </tr>
    <tr>
      <td>We are party to an <font color="blue">agreement</font>     with SPAH which grants <font color="blue">distribution</font> and <font color="blue">marketing rights</font> in the US for our     canine <font color="blue">heartworm</font> preventive product, TRI-HEART Chewable Tablets</td>
    </tr>
    <tr>
      <td><font color="blue">AgriLabs     </font>has the exclusive right to <font color="blue">sell certain</font> of our <font color="blue">bovine vaccines</font> in the United     States, Africa, China, Mexico and Taiwan</td>
    </tr>
    <tr>
      <td><font color="blue">Novartis Agro KK </font>markets and     <font color="blue">distributes</font> our <font color="blue">SOLO STEP CH </font><font color="blue">heartworm</font> test in Japan</td>
    </tr>
    <tr>
      <td>Furthermore, there may be nothing to prevent these <font color="blue">partners from</font>     <font color="blue">pursuing alternative <font color="blue">technologies</font></font> or products that <font color="blue">may <font color="blue">compete with</font></font> our     products  in  current or future <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>In the future, third-party     marketing assistance may not be <font color="blue">available on</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>If     any of these events occur, we may not be able to <font color="blue">commercialize</font> our products     and our <font color="blue">sales will decline</font></td>
    </tr>
    <tr>
      <td>In addition, both our <font color="blue"><font color="blue">agreement</font>s</font> with SPAH and     AgriLabs require us to <font color="blue">potentially</font> <font color="blue">pay penalties</font> if we are unable to supply     <font color="blue">product over</font> an <font color="blue">extended period</font> of time</td>
    </tr>
    <tr>
      <td>Many of our expenses are fixed and if factors beyond our control cause our     revenue to fluctuate, this <font color="blue">fluctuation</font> could cause greater than expected     losses, cash flow and liquidity shortfalls</td>
    </tr>
    <tr>
      <td>We believe that our future operating results <font color="blue">will fluctuate on</font> a quarterly     <font color="blue">basis due</font> to a variety of <font color="blue">factors which</font> are <font color="blue">generally</font> beyond our control,     including:         •                   supply  of  products from <font color="blue">third party</font> suppliers or     <font color="blue">termination</font> of <font color="blue">such relationships</font>;       •                  the <font color="blue">introduction</font> of <font color="blue">new products</font> by our <font color="blue">competitors</font> or by     us;       •                   <font color="blue">competition</font> and pricing pressures from <font color="blue">competitive</font>     products;       •                  our ability to maintain relationships with <font color="blue"><font color="blue">distributor</font>s</font>;       •                  large <font color="blue">customers failing</font> to <font color="blue">purchase at historical levels</font>,     including changes in <font color="blue">distributor</font> purchasing patterns and <font color="blue">inventory levels</font>;       •                  <font color="blue">fundamental</font> shifts in <font color="blue">market demand</font>;       •                  <font color="blue">manufacturing</font> delays;       •                  <font color="blue">shipment problems</font>;       •                  <font color="blue">regulatory</font> and other delays in <font color="blue">product <font color="blue">development</font></font>;       •                  <font color="blue">product recalls</font> or other <font color="blue">issues which may raise</font> our     costs;       •                  changes in our reputation and/or market <font color="blue">acceptance</font> of our     current or <font color="blue">new products</font>; and       •                  changes in the mix of <font color="blue">products sold</font></td>
    </tr>
    <tr>
      <td>We have high operating expenses for personnel, marketing and new product     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If any of     the  <font color="blue">factors listed</font> above cause our revenues to decline, our operating     results could be <font color="blue"><font color="blue">substantially</font> harm</font>ed</td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________         We have <font color="blue">historically</font> not <font color="blue"><font color="blue">consistently</font> generate</font>d positive <font color="blue">cash flow from</font>     <font color="blue">operations</font> and may need <font color="blue"><font color="blue">additional</font> capital</font> and any required <font color="blue">capital may</font> not     be <font color="blue">available on</font> acceptable terms or at all</td>
    </tr>
    <tr>
      <td>If  our  actual  performance  deviates  from our operating plan, which     anticipates we will be profitable in fiscal 2006 as a whole, we may be     required to raise <font color="blue"><font color="blue">additional</font> capital</font> in the future</td>
    </tr>
    <tr>
      <td>If <font color="blue">necessary</font>, we expect     to raise these <font color="blue"><font color="blue"><font color="blue">additional</font> funds</font> through one</font> or more of the following:  (1)     sale  of equity or debt securities; (2) obtaining <font color="blue">new loans secured by</font>     unencumbered  assets,  or  <font color="blue">refinancing</font>  <font color="blue">loans currently outstanding on</font>     properties with historical appraised values <font color="blue"><font color="blue">significant</font>ly</font> in excess of     related debt; (3) sale of assets, products or <font color="blue">marketing rights</font>; and (4)     licensing of <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>There is no guarantee that <font color="blue"><font color="blue">additional</font> capital</font> will     be <font color="blue">available from</font> these <font color="blue">sources on</font> acceptable terms, if at all, and certain     of  these <font color="blue">sources may</font> require <font color="blue">approval by existing lenders</font></td>
    </tr>
    <tr>
      <td>The public     <font color="blue">markets may</font> be <font color="blue">unreceptive</font> to <font color="blue"><font color="blue">equity financing</font>s</font> and we may not be able to     obtain <font color="blue"><font color="blue">additional</font> private equity</font> or <font color="blue">debt financing</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">equity financing</font>     <font color="blue">would likely</font> be dilutive to <font color="blue">stockholders</font> and <font color="blue">additional</font> <font color="blue">debt financing</font>, if     available, may include <font color="blue">restrictive covenants</font> and <font color="blue">increased interest rates</font>     that <font color="blue">would limit</font> our currently planned <font color="blue">operations</font> and strategies</td>
    </tr>
    <tr>
      <td>We may not     find any <font color="blue"><font color="blue">third parties</font> interested</font> in licensing our <font color="blue"><font color="blue">intellectual</font> property</font> or     purchasing any of our assets, products or <font color="blue">marketing rights</font> in a timely     manner, or at all</td>
    </tr>
    <tr>
      <td>If we <font color="blue">relinquish rights</font> to certain of our <font color="blue">intellectual</font>     property, or <font color="blue">sell certain</font> of our assets, products or <font color="blue">marketing rights</font> it may     limit our <font color="blue">future prospects</font></td>
    </tr>
    <tr>
      <td>Additionally, amounts we expect to be available     under our <font color="blue">existing <font color="blue">revolving line</font></font> of credit may not be available and other     lenders  could  refuse  to  provide us with <font color="blue">additional</font> <font color="blue">debt financing</font></td>
    </tr>
    <tr>
      <td>Furthermore, even if <font color="blue"><font color="blue">additional</font> capital</font> is available, it may not be of the     magnitude required to meet our needs under these or other scenarios</td>
    </tr>
    <tr>
      <td>If     <font color="blue"><font color="blue">additional</font> funds</font> are required and are not available, it <font color="blue">would likely</font> have a     material adverse effect on our business, <font color="blue">financial condition</font> and our ability     to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td><font color="blue">Interpretation  </font>of  existing  <font color="blue">legislation</font>,  <font color="blue">regulations</font>  and  rules or     <font color="blue">implementation</font> of future <font color="blue">legislation</font>, <font color="blue">regulations</font> and rules could cause our     costs to increase or could harm us in other ways</td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”) has increased our required     <font color="blue"><font color="blue">administrative</font> actions as</font> a <font color="blue">public company</font></td>
    </tr>
    <tr>
      <td>The increase in general and     <font color="blue"><font color="blue">administrative</font> costs</font> of <font color="blue">complying with</font> Sarbanes-Oxley <font color="blue">will depend on how</font> it     is <font color="blue">interpreted over</font> time</td>
    </tr>
    <tr>
      <td>Of particular concern are the level and timing of     standards  for <font color="blue">internal control evaluation</font> and reporting <font color="blue">adopted under</font>     Section 404 of Sarbanes-Oxley</td>
    </tr>
    <tr>
      <td>If our regulators and/or auditors adopt or     interpret more <font color="blue">stringent standards than</font> we are anticipating, we and/or our     <font color="blue">auditors may</font> be unable to conclude that our <font color="blue"><font color="blue">internal controls</font> over financial</font>     reporting are designed and operating <font color="blue"><font color="blue">effective</font>ly</font>, which could <font color="blue">adversely</font>     <font color="blue">affect investor confidence</font> in our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Even if we and our     auditors are able to conclude that our <font color="blue"><font color="blue">internal controls</font> over financial</font>     reporting are designed and operating <font color="blue"><font color="blue">effective</font>ly</font> in such a circumstance, our     general and <font color="blue"><font color="blue">administrative</font> costs</font> are likely to increase</td>
    </tr>
    <tr>
      <td>We may be required     to obtain an audit of our <font color="blue">internal controls</font> for the year ending <font color="blue">December </font>31,     2006  if  we  are an <font color="blue">accelerated filer as defined by</font> Rule 12b-2 of the     <font color="blue">Securities Exchange Act </font>of 1934, as amended, on June 30, 2006, and, if so,     our general and <font color="blue"><font color="blue">administrative</font> costs</font> are likely to increase in 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Actions     </font>by other entities, such as enhanced rules to maintain our <font color="blue">listing on</font> the     <font color="blue">Nasdaq Capital Market</font>, <font color="blue">could also</font> increase our general and <font color="blue">administrative</font>     costs, as could further legislative action</td>
    </tr>
    <tr>
      <td>We may not be able to achieve <font color="blue">sustained <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>Prior to 2005, we have incurred net losses on an <font color="blue">annual basis</font> since our     inception  in 1988 and, as of <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated</font>     deficit of dlra209dtta8 million</td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>our positive net income in 2005     and  our <font color="blue">expectation</font> of <font color="blue">profitability</font> for 2006 as a whole, we have not     <font color="blue">consistently</font> achieved <font color="blue">profitability</font> on an <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>Our ability to be     profitable  in  <font color="blue">future periods will depend</font>, in part, on our ability to     increase  sales in our <font color="blue">Core Companion Animal Health </font>segment, including     maintaining  and growing our <font color="blue">installed base</font> of <font color="blue">instruments</font> and related     <font color="blue">consumables</font>, to maintain or increase gross margins and to <font color="blue">at least limit</font> the     increase in our operating expenses to a <font color="blue">reasonable level</font></td>
    </tr>
    <tr>
      <td>Even if we achieve     <font color="blue">profitability</font>, we may not be able to sustain or increase <font color="blue">profitability</font> on a     quarterly or <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>If we cannot achieve or                                           16     ______________________________________________________________________         sustain <font color="blue">profitability</font> for an <font color="blue">extended period</font>, we may not be able to fund our     expected cash needs, including the repayment of debt as it comes due, or     continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">often depend on <font color="blue">third parties</font></font> for products we intend to introduce in the     future</td>
    </tr>
    <tr>
      <td>If our <font color="blue">current relationships</font> and <font color="blue">collaborations</font> are not successful,     we may not be able to introduce the products we intend to in the future</td>
    </tr>
    <tr>
      <td>We  are <font color="blue">often dependent on <font color="blue">third parties</font></font> and <font color="blue"><font color="blue">collaborative</font> partners</font> to     <font color="blue">successfully</font> and timely perform research and <font color="blue">development</font> <font color="blue">activities</font> to     <font color="blue">successfully</font>  develop  <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>For example, we jointly developed     point-of-care <font color="blue">diagnostic</font> products with Quidel, and Quidel <font color="blue">manufacture</font>s these     products</td>
    </tr>
    <tr>
      <td>In  other  cases,  we have discussed Heska marketing in the     <font color="blue">veterinary</font> market an instrument being developed by a <font color="blue">third party</font> for use in     the <font color="blue">human health care market</font></td>
    </tr>
    <tr>
      <td>In the future, one or more of these third     parties or <font color="blue"><font color="blue">collaborative</font> partners</font> may not complete research and <font color="blue">development</font>     <font color="blue">activities</font> in a <font color="blue">timely fashion</font>, or at all</td>
    </tr>
    <tr>
      <td>Even if these <font color="blue">third parties</font> are     successful in their research and <font color="blue">development</font> <font color="blue">activities</font>, we may not be able     to  come to an economic <font color="blue">agreement</font> with them</td>
    </tr>
    <tr>
      <td>If these <font color="blue">third parties</font> or     <font color="blue"><font color="blue">collaborative</font> partners</font> fail to complete research and <font color="blue">development</font> <font color="blue">activities</font>,     fail to complete them in a <font color="blue">timely fashion</font>, or if we are unable to negotiate     economic <font color="blue"><font color="blue">agreement</font>s</font> with such <font color="blue">third parties</font> or <font color="blue"><font color="blue">collaborative</font> partners</font>, our     ability  to introduce new <font color="blue">products will</font> be <font color="blue">impacted negatively</font> and our     <font color="blue">revenues may decline</font></td>
    </tr>
    <tr>
      <td>We operate in a highly <font color="blue">competitive</font> industry, which could render our products     obsolete or <font color="blue">substantially</font> limit the volume of products that we sell</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">would limit</font> our ability to compete and achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The market in which we compete is intensely <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font>     include  <font color="blue">independent</font>  animal health companies and <font color="blue">major pharmaceutical</font>     companies  that  have  animal  health  divisions</td>
    </tr>
    <tr>
      <td>We <font color="blue">also <font color="blue">compete with</font></font>     <font color="blue">independent</font>, <font color="blue">third party</font> <font color="blue"><font color="blue">distributor</font>s</font>, including <font color="blue"><font color="blue">distributor</font>s</font> who sell     <font color="blue">products under</font> their own <font color="blue">private labels</font></td>
    </tr>
    <tr>
      <td>In the point-of-care <font color="blue">diagnostic</font>     testing market, our major <font color="blue">competitors</font> include IDEXX, Abaxis, Inc, Agenix     Limited and Synbiotics Corporation</td>
    </tr>
    <tr>
      <td>The products <font color="blue">manufacture</font>d by our OVP     segment for sale by <font color="blue">third parties</font> <font color="blue">compete with</font> similar <font color="blue">products offered by</font> a     number  of  other  companies, some of which have <font color="blue">substantially</font> greater     financial, technical, research and other <font color="blue">resources than us</font> and may have more     established marketing, sales, <font color="blue">distribution</font> and service <font color="blue">organization</font>’s than     our OVP segment’s customers</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may have <font color="blue"><font color="blue">facilities</font> with</font> similar     <font color="blue">capabilities</font> to our OVP segment, which they may operate at a lower unit     price to their customers, which could cause us to <font color="blue">lose customers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies     </font>with a <font color="blue">significant</font> presence in the companion animal health market, such as     Bayer AG,  Intervet International bv (a unit of Akzo Nobel NV), Merial     Limited, Novartis AG, Pfizer Inc, Schering-Plough Corporation,  Virbac SA     and Wyeth (formerly American Home Products), may be marketing or developing     products  that <font color="blue">compete with</font> our products or would <font color="blue">compete with</font> them if     developed</td>
    </tr>
    <tr>
      <td>These and other <font color="blue">competitors</font> may have <font color="blue">substantially</font> greater     financial,  technical,  research  and other resources and larger, more     established marketing, sales, <font color="blue">distribution</font> and service <font color="blue">organization</font>s than we     do</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may offer broader <font color="blue">product line</font>s and have <font color="blue">greater name</font>     <font color="blue">recognition than</font> we do</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may develop or <font color="blue">market <font color="blue">technologies</font></font>     or products that are more <font color="blue">effective</font> or <font color="blue">commercially attractive than</font> our     current  or  <font color="blue">future products</font> or that would render our <font color="blue">technologies</font> and     <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">additional</font> <font color="blue">competition</font> could come from new     entrants to the <font color="blue">animal health care market</font></td>
    </tr>
    <tr>
      <td>Moreover, we may not have the     <font color="blue">financial resources</font>, technical expertise or marketing, <font color="blue">distribution</font> or     support <font color="blue">capabilities</font> to compete <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We believe that one of our     largest <font color="blue">competitors</font>, IDEXX, <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> prohibits</font> its <font color="blue"><font color="blue">distributor</font>s</font> from     selling <font color="blue">competitive</font> products, including our <font color="blue">diagnostic</font> <font color="blue">instruments</font> and     <font color="blue"><font color="blue">heartworm</font> <font color="blue">diagnostic</font></font> tests</td>
    </tr>
    <tr>
      <td>If we fail to compete <font color="blue">successfully</font>, our ability     to  achieve  sustained  <font color="blue">profitability</font>  will  be  limited and sustained     <font color="blue">profitability</font>, or <font color="blue">profitability</font> at all, may not be possible</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________         The loss of <font color="blue">significant</font> customers could harm our operating results</td>
    </tr>
    <tr>
      <td>Although no single customer accounted for more than 10prca of our <font color="blue">consolidated</font>     revenue or <font color="blue">accounts</font> receivable for either of the <font color="blue">twelve month periods</font> ended     <font color="blue">December </font> 31,  2004  and 2005, revenue from our <font color="blue">contract with</font> <font color="blue">AgriLabs     </font>comprised <font color="blue">approximately</font> 15prca of <font color="blue">consolidated</font> revenue in 2003</td>
    </tr>
    <tr>
      <td>While we do not     have any other customers who represented more than 10prca of <font color="blue">revenues over</font> the     <font color="blue">last three years</font>, the loss of <font color="blue">significant</font> customers who, for example, are     <font color="blue">historically</font> large purchasers or who are considered leaders in their field     could damage our business and financial results</td>
    </tr>
    <tr>
      <td>For example, on March 8,     2006, Henry Schein, Inc</td>
    </tr>
    <tr>
      <td>(“Henry Schein”) announced a definitive <font color="blue">agreement</font>     to  acquire  NLS  Animal  Health  (“NLS”)</td>
    </tr>
    <tr>
      <td><font color="blue">Henry Schein </font>is our largest     <font color="blue">independent</font>  <font color="blue">third party</font> <font color="blue">distributor</font> and NLS is a <font color="blue">distributor</font> of <font color="blue">IDEXX     </font>products</td>
    </tr>
    <tr>
      <td>We believe IDEXX <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> prohibits</font> its <font color="blue"><font color="blue">distributor</font>s</font> from     selling <font color="blue">competitive</font> products, including our <font color="blue">diagnostic</font> <font color="blue">instruments</font> and     <font color="blue"><font color="blue">heartworm</font> <font color="blue">diagnostic</font></font> tests</td>
    </tr>
    <tr>
      <td>If <font color="blue">Henry Schein </font>were to decide not to carry our     full  <font color="blue">product line</font> due to <font color="blue">prohibitions</font> IDEXX <font color="blue"><font color="blue">effective</font>ly</font> places on its     <font color="blue"><font color="blue">distributor</font>s</font> or for other reasons, our sales <font color="blue"><font color="blue">would likely</font> suffer</font> as it is     unlikely we <font color="blue">would completely recover</font> the <font color="blue">corresponding lower sales</font> to Henry     Schein <font color="blue">through direct sales</font> and <font color="blue">sales through</font> other <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>We may face costly <font color="blue"><font color="blue">intellectual</font> property</font> or other <font color="blue">legal disputes</font>, or our     <font color="blue">technology</font> or that of our suppliers or <font color="blue"><font color="blue">collaborators</font> may become</font> the subject     of <font color="blue">legal action</font></td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue"><font color="blue">effective</font>ly</font> will depend in part on our ability to     develop and maintain <font color="blue"><font color="blue">proprietary</font> aspects</font> of our <font color="blue">technology</font> and either to     operate <font color="blue">without infringing</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others or to obtain     rights to <font color="blue">technology</font> owned by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">United States </font>and     foreign-issued patents and are currently prosecuting patent <font color="blue">applications</font> in     the  United  States  and various foreign countries</td>
    </tr>
    <tr>
      <td>Our <font color="blue">pending patent</font>     <font color="blue">applications</font> may not result in the issuance of any patents or any issued     patents  that  will  offer protection against <font color="blue">competitors</font> with similar     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Patents  </font>we  receive  may  be  challenged, invalidated or     <font color="blue">circumvented</font> in the future or the rights created by those <font color="blue">patents may</font> not     provide a <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>We also rely on trade secrets, technical     know-how and <font color="blue">continuing invention</font> to develop and maintain our <font color="blue">competitive</font>     position</td>
    </tr>
    <tr>
      <td>Others  may  <font color="blue">independent</font>ly develop <font color="blue">substantially</font> equivalent     <font color="blue">proprietary</font> information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our trade     secrets</td>
    </tr>
    <tr>
      <td>We  may  become  subject  to <font color="blue"><font color="blue">additional</font> patent <font color="blue">infringement</font></font> claims and     <font color="blue">litigation</font>  in  the  United  States or other countries or <font color="blue">interference</font>     <font color="blue"><font color="blue">proceedings</font> conducted</font> in the <font color="blue">United States </font>Patent and Trademark Office, or     USPTO, to determine the priority of <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>The defense and <font color="blue">prosecution</font>     of <font color="blue"><font color="blue">intellectual</font> property</font> suits, USPTO <font color="blue">interference</font> <font color="blue">proceedings</font>, and related     legal  and  <font color="blue">administrative</font>  <font color="blue">proceedings</font> are costly, time-consuming and     <font color="blue">distracting</font></td>
    </tr>
    <tr>
      <td>We may also need to pursue <font color="blue">litigation</font> to enforce any patents     issued to us or our <font color="blue"><font color="blue">collaborative</font> partners</font>, to <font color="blue">protect trade secrets</font> or     know-how owned by us or our <font color="blue"><font color="blue">collaborative</font> partners</font>, or to determine the     enforceability, scope and validity of the <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">litigation</font> or <font color="blue">interference</font> proceeding will result in substantial expense to     us and <font color="blue">significant</font> diversion of the efforts of our technical and <font color="blue">management</font>     personnel</td>
    </tr>
    <tr>
      <td>Any  adverse  de<font color="blue">termination</font>  in <font color="blue">litigation</font> or <font color="blue">interference</font>     <font color="blue">proceedings</font> could subject us to <font color="blue">significant</font> liabilities to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Further, as a result of <font color="blue">litigation</font> or other <font color="blue">proceedings</font>, we may be required     to  seek  licenses  from  third  <font color="blue">parties which may</font> not be <font color="blue">available on</font>     <font color="blue">commercially reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>We license <font color="blue">technology</font> from a number of <font color="blue">third parties</font>, including New England     Biolabs, Inc</td>
    </tr>
    <tr>
      <td>and Roche Molecular Systems, Inc, as well as a number of     research  <font color="blue">institutions</font> and <font color="blue">universities</font></td>
    </tr>
    <tr>
      <td>The majority of these license     <font color="blue"><font color="blue">agreement</font>s</font> impose due diligence or milestone <font color="blue">obligations</font> on us, and in some     cases impose minimum royalty and/or sales <font color="blue">obligations</font> on us, in order for us     to maintain our <font color="blue">rights under</font> these <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">products may</font> incorporate</font>     <font color="blue">technologies</font>  that  are  the  subject of patents issued to, and patent     <font color="blue">applications</font> filed by, others</td>
    </tr>
    <tr>
      <td>As is typical in our industry, from time to     time we and our <font color="blue">collaborators</font> have received, and may in the future receive,     notices from <font color="blue">third parties</font> claiming <font color="blue">infringement</font> and <font color="blue">invitations</font> to take     licenses under <font color="blue">third party</font> patents</td>
    </tr>
    <tr>
      <td>While we currently do not have any     unresolved notices of <font color="blue">infringement</font>, there is no                                           18     ______________________________________________________________________         assurance that <font color="blue">there will</font> be none in the future</td>
    </tr>
    <tr>
      <td>Any <font color="blue">legal action</font> against us     or our <font color="blue">collaborators</font> may require us or our <font color="blue">collaborators</font> to obtain one or     more  licenses  in order to market or <font color="blue">manufacture</font> affected products or     services</td>
    </tr>
    <tr>
      <td>However,  we or our <font color="blue">collaborators</font> may not be able to obtain     licenses for <font color="blue">technology</font> patented by others on <font color="blue">commercially reasonable terms</font>,     or at all, we may not be able to develop <font color="blue">alternative approaches</font> if unable to     obtain licenses, or current and <font color="blue">future licenses may</font> not be adequate for the     operation of our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue">necessary</font> licenses or to     identify and implement <font color="blue">alternative approaches</font> could prevent us and our     <font color="blue">collaborators</font> from commercializing our <font color="blue">products under</font> <font color="blue">development</font> and could     <font color="blue"><font color="blue">substantially</font> harm</font> our business</td>
    </tr>
    <tr>
      <td>We may also face <font color="blue">legal disputes</font> relating to other areas of our business</td>
    </tr>
    <tr>
      <td>These <font color="blue">disputes may</font> require <font color="blue">significant</font> expenditures on our part and could     have  material  <font color="blue">adverse consequences on</font> our business in the case of an     <font color="blue">unfavorable ruling</font> or settlement</td>
    </tr>
    <tr>
      <td>For example, on <font color="blue">September </font>9, 2005, United     Vaccines, Inc</td>
    </tr>
    <tr>
      <td>(“United”), a customer of our OVP segment, filed a lawsuit in     Madison,  Wisconsin against our Diamond Animal Health, Inc</td>
    </tr>
    <tr>
      <td>subsidiary     (“Diamond”) and Heska <font color="blue">Corporation </font>alleging various claims, including breach     of contract and breach of warranty, and <font color="blue">demanding compensatory</font> and punitive     damages</td>
    </tr>
    <tr>
      <td>On October 20, 2005, we filed a motion to <font color="blue">dismiss certain</font> claims     against  Diamond and all claims against Heska, as well as an answer to     United’s  claims,  <font color="blue">affirmative defenses</font> and <font color="blue">counterclaims on behalf</font> of     Diamond</td>
    </tr>
    <tr>
      <td>Both <font color="blue">sides <font color="blue">subsequently</font> filed amended complaints</font> and the matter is     ongoing</td>
    </tr>
    <tr>
      <td>While we intend to pursue the matter <font color="blue">vigorously</font> and believe we are     entitled to damages from United and that United is not entitled to damages     from Heska or Diamond, there can be no assurance the <font color="blue">ultimate resolution</font> of     this <font color="blue">case will reflect</font> our <font color="blue">current beliefs</font></td>
    </tr>
    <tr>
      <td>Our  future  revenues  depend  on  successful  research,  <font color="blue">development</font>,     <font color="blue">commercialization</font> and/or market <font color="blue">acceptance</font>, any of which can be <font color="blue">slower than</font>     we expect or may not occur</td>
    </tr>
    <tr>
      <td>The research, <font color="blue">development</font> and <font color="blue">regulatory</font> approval process for many of our     products is extensive and may take <font color="blue">substantially</font> longer than we anticipate</td>
    </tr>
    <tr>
      <td>New products that we are developing for the     <font color="blue">veterinary</font> marketplace may not perform up to our <font color="blue">expectation</font>s</td>
    </tr>
    <tr>
      <td>Because we     have   limited   resources   to  devote  to  product  <font color="blue">development</font>  and     <font color="blue">commercialization</font>, any delay in the research or <font color="blue">development</font> of one product     or <font color="blue">reallocation</font> of resources to <font color="blue">product <font color="blue">development</font></font> efforts that prove     <font color="blue">unsuccessful</font>  may delay or <font color="blue">jeopardize</font> the <font color="blue">development</font> of other product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">successfully</font> develop <font color="blue">new products</font> and <font color="blue">bring them</font>     to market in a <font color="blue">timely manner</font>, our ability to <font color="blue">generate <font color="blue">additional</font> revenue</font>     <font color="blue">will decrease</font></td>
    </tr>
    <tr>
      <td>Even if we are successful in the research and <font color="blue">development</font> of a product, we     may experience delays in <font color="blue">commercialization</font> and/or market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>For     example, there may be delays in producing large volumes of a product or     <font color="blue">veterinarians</font> may be slow to adopt a product</td>
    </tr>
    <tr>
      <td>The latter is <font color="blue">particularly</font>     likely where there is <font color="blue">no comparable product available</font> or <font color="blue">historical use</font> of     such a product</td>
    </tr>
    <tr>
      <td>For example, while we believe our ERD-HEALTHSCREEN urine     tests for dogs and <font color="blue">cats represent</font> a <font color="blue">significant</font> scientific breakthrough in     companion  animal annual health examinations, market <font color="blue">acceptance</font> of the     product has been <font color="blue"><font color="blue">significant</font>ly</font> <font color="blue">slower than</font> we anticipated</td>
    </tr>
    <tr>
      <td>The ultimate     adoption of a new product by <font color="blue">veterinarians</font>, the rate of <font color="blue">such adoption</font> and     the extent <font color="blue">veterinarians</font> choose to <font color="blue">integrate such</font> a <font color="blue">product into</font> their     practice are all <font color="blue">important factors</font> in the <font color="blue">economic success</font> of one of our new     products and are factors that we do not control to a large extent</td>
    </tr>
    <tr>
      <td>If our     products do not achieve a <font color="blue">significant</font> level of market <font color="blue">acceptance</font>, demand for     our <font color="blue">products will</font> not develop as expected and our <font color="blue">revenues will</font> be lower     than we anticipate</td>
    </tr>
    <tr>
      <td>Our stock price has <font color="blue">historically</font> experienced high <font color="blue">volatility</font>, which may     increase in the future, and <font color="blue">which could affect</font> our ability to <font color="blue">raise capital</font>     in the future or make it <font color="blue">difficult</font> for investors to sell their shares</td>
    </tr>
    <tr>
      <td>The  securities  markets have experienced <font color="blue">significant</font> price and volume     <font color="blue">fluctuation</font>s  and the <font color="blue"><font color="blue">market price</font>s</font> of securities of many microcap and     <font color="blue">smallcap companies</font> have in the past been, and can in the future be                                           19     ______________________________________________________________________         expected to be, <font color="blue">especially volatile</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations     </font>in the <font color="blue">trading price</font> or liquidity of our <font color="blue">common stock</font> may <font color="blue">adversely</font> affect     our ability to <font color="blue">raise capital</font> through future <font color="blue"><font color="blue">equity financing</font>s</font></td>
    </tr>
    <tr>
      <td>Factors that     may have a <font color="blue">significant</font> impact on the <font color="blue">market price</font> and <font color="blue">marketability</font> of our     <font color="blue">common stock</font> include:           •                  <font color="blue">stock sales by</font> large <font color="blue">stockholders</font> or by insiders;       •                  our quarterly operating results, including as compared to     our revenue, earnings or other guidance and in <font color="blue">comparison</font> to historical     results;       •                  <font color="blue">termination</font> of our <font color="blue">third party</font> supplier relationships;       •                   <font color="blue">announcements</font>  of <font color="blue">technological innovations</font> or new     products by our <font color="blue">competitors</font> or by us;       •                  <font color="blue">litigation</font>;       •                  <font color="blue">regulatory</font> <font color="blue">development</font>s, including delays in product     <font color="blue">introduction</font>s;       •                  <font color="blue">development</font>s in our relationships with <font color="blue">collaborative</font>     partners;       •                   <font color="blue">development</font>s  or  disputes  <font color="blue">concerning</font>  patents or     <font color="blue"><font color="blue">proprietary</font> rights</font>;       •                   <font color="blue">availability</font>  of  our <font color="blue">revolving line</font> of credit and     <font color="blue"><font color="blue">compliance with</font> debt covenants</font>;       •                  releases of reports <font color="blue">by securities analysts</font>;       •                  changes in <font color="blue">regulatory</font> policies;       •                  economic and other <font color="blue">external factors</font>; and       •                  <font color="blue">general market <font color="blue">conditions</font></font></td>
    </tr>
    <tr>
      <td>In  the past, following periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a     company’s securities, securities class action <font color="blue">litigation</font> has often been     instituted</td>
    </tr>
    <tr>
      <td>If a securities class action suit is filed against us, it is     likely we would incur substantial legal fees and our <font color="blue">management</font>’s attention     and resources would be diverted from operating our business in order to     respond to the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is listed on the <font color="blue"><font color="blue">Nasdaq Capital Market</font> </font>and we may not be     able to maintain that listing, which may make it more <font color="blue">difficult</font> for you to     sell your shares</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is listed on the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Nasdaq </font>has     <font color="blue">several quantitative</font> and qualitative <font color="blue"><font color="blue">requirement</font>s</font> companies must <font color="blue">comply with</font>     to maintain this listing, including a dlra1dtta00 minimum bid price</td>
    </tr>
    <tr>
      <td>While we     believe we are currently in <font color="blue">compliance with</font> all Nasdaq <font color="blue"><font color="blue">requirement</font>s</font>, we have     not <font color="blue">always been able</font> to maintain compliance in the past and there can be no     assurance we will maintain compliance in the future</td>
    </tr>
    <tr>
      <td>For example, in 2005 we     received <font color="blue">two <font color="blue">communications from</font></font> Nasdaq <font color="blue">advising us</font> we had failed to comply     with the minimum dlra1dtta00 per share <font color="blue">bid price <font color="blue">requirement</font></font> and the dlra35 million     <font color="blue">minimum value</font> of listed securities <font color="blue">requirement</font>, respectively</td>
    </tr>
    <tr>
      <td>While we     <font color="blue">subsequently</font>  received  <font color="blue">communications from</font> Nasdaq <font color="blue">advising us</font> we have     <font color="blue">regained compliance</font> in <font color="blue">both matters</font> and that <font color="blue">both matters</font> are now closed,     there can be no assurance we <font color="blue">will continue</font> to meet these <font color="blue"><font color="blue">requirement</font>s</font> or     other <font color="blue"><font color="blue">requirement</font>s</font> in the future</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">delisted from</font> the Nasdaq Capital     Market,  our  common  stock  may be considered a <font color="blue">penny stock under</font> the     <font color="blue">regulations</font> of the SEC and would therefore be subject to rules that impose     <font color="blue">additional</font>  sales practice <font color="blue"><font color="blue">requirement</font>s</font> on broker-dealers who sell our     securities</td>
    </tr>
    <tr>
      <td>The  <font color="blue">additional</font>  burdens  imposed upon broker-dealers may     discourage broker-dealers from effecting <font color="blue">transactions</font> in our <font color="blue">common stock</font>,     <font color="blue">which could severely limit market liquidity</font> of the <font color="blue">common stock</font> and your     ability  to  sell our securities in the <font color="blue">secondary market</font></td>
    </tr>
    <tr>
      <td>This lack of     <font color="blue">liquidity would also</font> make it more <font color="blue">difficult</font> for us to <font color="blue">raise capital</font> in the     future</td>
    </tr>
    <tr>
      <td>If we are unable to maintain <font color="blue">various financial</font> and other <font color="blue">covenants under</font> our     credit facility <font color="blue">agreement</font> we will be unable to borrow any funds under the     <font color="blue">agreement</font> and fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Under our credit and security <font color="blue">agreement</font> with Wells Fargo, as amended and     restated in <font color="blue">December </font>2005 and under prior <font color="blue"><font color="blue">agreement</font>s</font>, we are required to     <font color="blue">comply with</font> <font color="blue">various financial</font> and non-financial covenants in order to borrow     under the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of <font color="blue">borrowings under</font> this <font color="blue">agreement</font> is                                           20     ______________________________________________________________________         essential to continue to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Among the financial covenants     is a <font color="blue">requirement</font> to maintain minimum liquidity (cash plus excess borrowing     base) of dlra1dtta5 million</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue"><font color="blue">requirement</font>s</font> include covenants for minimum     <font color="blue">capital monthly</font> and <font color="blue">minimum net income quarterly</font></td>
    </tr>
    <tr>
      <td>Although we believe we     will  be  able to maintain <font color="blue">compliance with</font> all these covenants and any     covenants we <font color="blue">may negotiate</font> in the future, there can be <font color="blue">no assurance thereof</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">always been able</font> to maintain <font color="blue">compliance with</font> all covenants in     the past, including in the <font color="blue">first four months</font> of 2005 and on June 30, 2005</td>
    </tr>
    <tr>
      <td><font color="blue">Wells Fargo </font><font color="blue">granted us</font> a waiver of non-compliance in each case</td>
    </tr>
    <tr>
      <td>However,     there can be no assurance we will be able to obtain similar waivers or other     <font color="blue">modifications</font> if needed in the future</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> any of the covenants, representations or warranties,     or failure to <font color="blue">modify them</font> to allow future compliance, could result in our     being in <font color="blue">default under</font> the loan and could cause all <font color="blue">outstanding amounts</font> and     <font color="blue">loans with</font> our other lenders to <font color="blue">become immediately due</font> and payable, or     impact our ability to <font color="blue">borrow under</font> the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We intend to rely on     available <font color="blue">borrowings under</font> the credit and security <font color="blue">agreement</font> to fund our     <font color="blue">operations</font>  in the future</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">borrow funds under</font> this     <font color="blue">agreement</font>, we will need to raise <font color="blue"><font color="blue">additional</font> capital</font> from other sources to     continue our <font color="blue">operations</font>, which <font color="blue">capital may</font> not be <font color="blue">available on</font> acceptable     terms, or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining  </font>and maintaining <font color="blue">regulatory</font> approvals in order to market our     regulated <font color="blue">products may</font> be costly and delay the marketing and sales of our     products</td>
    </tr>
    <tr>
      <td>Many  of the products we develop, market or <font color="blue">manufacture</font> are subject to     extensive  <font color="blue">regulation by one</font> or more of the USDA, the FDA, the EPA and     foreign  <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> govern, among other     things,  the  <font color="blue">development</font>,  testing, <font color="blue">manufacturing</font>, labeling, storage,     pre-market approval, advertising, promotion, sale and <font color="blue">distribution</font> of our     products</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of these <font color="blue"><font color="blue">requirement</font>s</font> can take several years and time     needed to satisfy them may vary <font color="blue">substantially</font>, based on the type, <font color="blue">complexity</font>     and novelty of the product</td>
    </tr>
    <tr>
      <td>The effect of <font color="blue">government regulation may</font> be to delay or to <font color="blue">prevent marketing</font>     of our products for a considerable period of time and to <font color="blue">impose costly</font>     <font color="blue">procedures upon</font> our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We have experienced in the past, and may     experience in the future, <font color="blue">difficult</font>ies that <font color="blue">could delay</font> or <font color="blue">prevent us from</font>     obtaining the <font color="blue">regulatory</font> approval or license <font color="blue">necessary</font> to introduce or     market  our products</td>
    </tr>
    <tr>
      <td>Such delays in <font color="blue">approval may</font> cause us to forego a     <font color="blue">significant</font>  portion of a new product’s sales in its <font color="blue">first year due</font> to     <font color="blue">seasonality</font> and advanced booking periods associated with certain products</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval of our <font color="blue">products may</font> also impose limitations on the     indicated or <font color="blue">intended uses</font> for which our <font color="blue">products may</font> be marketed</td>
    </tr>
    <tr>
      <td>Among the <font color="blue">conditions</font> for certain <font color="blue">regulatory</font> approvals is the <font color="blue">requirement</font>     that our <font color="blue">facilities</font> and/or the <font color="blue">facilities</font> of our <font color="blue">third party</font> <font color="blue">manufacture</font>rs     conform  to  current  Good  Manufacturing Practices</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font>     <font color="blue">facilities</font> and those of our <font color="blue">third party</font> <font color="blue">manufacture</font>rs must also conform to     certain other <font color="blue">manufacturing</font> <font color="blue">regulations</font>, which include <font color="blue"><font color="blue">requirement</font>s</font> relating     to <font color="blue">quality control</font> and <font color="blue">quality assurance as well as maintenance</font> of records     and <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>The USDA, FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> strictly     enforce <font color="blue">manufacturing</font> <font color="blue"><font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></font> through periodic <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>If any <font color="blue">regulatory</font> authority determines that our <font color="blue">manufacturing</font> <font color="blue">facilities</font> or     those  of  our <font color="blue">third party</font> <font color="blue">manufacture</font>rs do not conform to <font color="blue">appropriate</font>     <font color="blue">manufacturing</font> <font color="blue"><font color="blue">requirement</font>s</font>, we or the <font color="blue">manufacture</font>rs of our <font color="blue">products may</font> be     subject to sanctions, including warning letters, <font color="blue">manufacturing</font> suspensions,     <font color="blue">product recalls</font> or seizures, injunctions, refusal to <font color="blue">permit products</font> to be     <font color="blue">imported into</font> or <font color="blue">exported out</font> of the United States, refusals of <font color="blue">regulatory</font>     <font color="blue">authorities</font> to <font color="blue">grant approval</font> or to allow us to <font color="blue">enter into government supply</font>     contracts, withdrawals of previously approved marketing <font color="blue">applications</font>, civil     fines and criminal <font color="blue">prosecution</font>s</td>
    </tr>
    <tr>
      <td>In addition, certain of our <font color="blue"><font color="blue">agreement</font>s</font>     require us to <font color="blue">pay penalties</font> if we are unable to <font color="blue">supply products</font>, including     for failure to maintain <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________         We  <font color="blue">depend on <font color="blue">key personnel</font></font> for our <font color="blue">future success</font></td>
    </tr>
    <tr>
      <td>If we lose our key     personnel or are unable to attract and retain <font color="blue">additional</font> personnel, we may     be unable to achieve our goals</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success</font> is <font color="blue">substantially</font> dependent on the efforts of our senior     <font color="blue">management</font>  and  other <font color="blue">key personnel</font>, including Dr</td>
    </tr>
    <tr>
      <td>Robert Grieve, our     <font color="blue">Chairman and Chief Executive Officer</font></td>
    </tr>
    <tr>
      <td>The loss of the services of members of     our senior <font color="blue">management</font> or other <font color="blue">key personnel</font> may <font color="blue"><font color="blue">significant</font>ly</font> delay or     prevent the <font color="blue">achievement</font> of our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Although we have an     <font color="blue">employment</font>  <font color="blue">agreement</font>  with many of these <font color="blue">individuals</font>, all are at-will     employees, which means that either the employee or Heska <font color="blue">may terminate</font>     <font color="blue">employment</font> at any time <font color="blue">without prior</font> notice</td>
    </tr>
    <tr>
      <td>If we lose the services of, or     fail  to  recruit,  <font color="blue">key personnel</font>, the growth of our business could be     <font color="blue">substantially</font> impaired</td>
    </tr>
    <tr>
      <td>We do not maintain key person <font color="blue">life insurance</font> for any     of our <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>to  financial  <font color="blue">accounting</font> standards may affect our results of     <font color="blue">operations</font> and cause us to change our business practices</td>
    </tr>
    <tr>
      <td>We  prepare our <font color="blue">financial statements</font> in <font color="blue">conformance with</font> <font color="blue">United States </font>    <font color="blue">generally</font>  accepted  <font color="blue">accounting</font>  principles, or GAAP These <font color="blue">accounting</font>     principles are <font color="blue">established by</font> and are subject to interpretation by the     Financial Accounting Standards Board, the American Institute of Certified     Public Accountants, the SEC and various bodies formed to interpret and     create <font color="blue">appropriate</font> <font color="blue">accounting</font> policies</td>
    </tr>
    <tr>
      <td>A change in those policies can have     a <font color="blue">significant</font> effect on our reported results and may affect our reporting of     <font color="blue">transactions</font> completed before a change is made <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Changes to those     rules may <font color="blue">adversely</font> affect our reported financial results or the way we     conduct our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">may face product returns</font> and product <font color="blue">liability</font> <font color="blue">litigation</font> in excess of or     not <font color="blue">covered by</font> our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>If we become subject to product     <font color="blue">liability</font> claims resulting <font color="blue">from defects</font> in our products, we may fail to     achieve market <font color="blue">acceptance</font> of our products and our sales could <font color="blue">substantially</font>     decline</td>
    </tr>
    <tr>
      <td>The testing, <font color="blue">manufacturing</font> and marketing of our <font color="blue">current products as well as</font>     those  currently  under <font color="blue">development</font> entail an <font color="blue">inherent risk</font> of product     <font color="blue">liability</font>  claims  and  associated  adverse  publicity</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>the     <font color="blue">introduction</font> of a product, adverse side <font color="blue">effects may</font> be discovered</td>
    </tr>
    <tr>
      <td><font color="blue">Adverse     </font>publicity regarding <font color="blue">such effects could affect sales</font> of our other products     for an <font color="blue">indeterminate</font> time period</td>
    </tr>
    <tr>
      <td>To date, we have not experienced any     material product <font color="blue">liability</font> claims, but any claim arising in the <font color="blue">future could</font>     <font color="blue"><font color="blue">substantially</font> harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font>product <font color="blue">liability</font> claims may     exceed the amount of our <font color="blue">insurance coverage</font> or may be <font color="blue">excluded from coverage</font>     under the terms of the policy</td>
    </tr>
    <tr>
      <td>We may not be able to continue to obtain     <font color="blue">adequate insurance at</font> a <font color="blue">reasonable cost</font>, if at all</td>
    </tr>
    <tr>
      <td>In the event that we are     held liable for a claim <font color="blue">against which</font> we are not indemnified or for damages     exceeding the dlra10 million limit of our <font color="blue">insurance coverage</font> or which results     in  <font color="blue">significant</font>  <font color="blue">adverse publicity against us</font>, we <font color="blue">may lose revenue</font>, be     required to make substantial <font color="blue">payments which could exceed</font> our financial     <font color="blue">capacity</font> and/or lose or fail to achieve market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Furthermore, our     <font color="blue"><font color="blue">agreement</font>s</font> with some suppliers of our <font color="blue">instruments</font> contain limited warranty     provisions, which may subject us to <font color="blue">liability</font> if a <font color="blue">supplier fails</font> to meet     its warranty <font color="blue">obligations</font> if a defect is traced to our instrument or if we     cannot  correct  errors  reported  during  the <font color="blue">warranty period</font></td>
    </tr>
    <tr>
      <td>If our     <font color="blue">contractual limitations</font> are unenforceable in a <font color="blue">particular jurisdiction</font>, a     successful claim could require us to pay substantial damages</td>
    </tr>
    <tr>
      <td>We may be held liable for the release of <font color="blue">hazardous</font> materials, which could     result in extensive <font color="blue">clean up costs</font> or <font color="blue">otherwise harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Certain  </font>of our products and <font color="blue">development</font> programs produced at the Iowa     <font color="blue">facility involve</font> the <font color="blue">controlled use</font> of <font color="blue">hazardous</font> and bio<font color="blue">hazardous</font> materials,     including chemicals, infectious disease agents and <font color="blue">various radioactive</font>     compounds</td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">safety procedures</font> for handling and     disposing  of  such  materials <font color="blue">comply with</font> the <font color="blue">standards prescribed by</font>     <font color="blue">applicable local</font>, state and federal <font color="blue">regulations</font>, we <font color="blue">cannot eliminate</font> the     risk of <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>In the     event of such an                                           22     ______________________________________________________________________         <font color="blue">accident</font>, we could be held liable for any fines, penalties, remediation     costs  or  other damages that result</td>
    </tr>
    <tr>
      <td>Our <font color="blue">liability</font> for the release of     <font color="blue">hazardous</font>  <font color="blue">materials could exceed</font> our resources, which could lead to a     shutdown of our <font color="blue">operations</font>, <font color="blue">significant</font> remediation costs and potential     legal <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>In addition, we may incur substantial costs to <font color="blue">comply with</font>     environmental <font color="blue">regulations</font> if we choose to expand our <font color="blue">manufacturing</font> <font color="blue">capacity</font></td>
    </tr>
  </tbody>
</table>